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Abstract: Multiple micronutrient supplementation (MMS) in pregnancy has previously been
associated with positive effects on fetal growth, but its value in high-income countries remains
controversial. In this study, we investigated effects of pregnancy MMS on offspring size at birth
and adiposity, along with risks of various maternal outcomes of pregnancy, using the prospective
Cambridge Baby Growth Study. Maternal MMS was reported in 528 out of 970 women who completed
pregnancy questionnaires. Gestational diabetes (GDM) was assessed using results from 75 g oral
glucose tolerance tests at week 28 of pregnancy. Offspring size at birth was assessed using standard
anthropometric measurements and adiposity using skinfold calipers. MMS was associated with
increased risk of developing GDM (risk ratio = 1.86 (1.13–3.08), p = 0.02), as well as increased offspring
size at birth in terms of weight (p = 0.03), head circumference (p = 0.04), and flank, and subscapular
and triceps skinfold thicknesses (p = 0.04, 0.03, and 0.003, respectively). There was no association
with quadriceps skinfold thickness (p = 0.2), suggesting that the increased adiposity was partially
regionalized. In women who underwent oral glucose tolerance testing, nearly all of these associations
were attenuated by adjusting for GDM. These results suggest that the increased offspring size at birth,
including (regionalized) adiposity associated with pregnancy, and MMS may be partially related to
the development of GDM.
Keywords: adiposity; development; fetal growth; gestational diabetes; minerals; vitamins
1. Introduction
Multiple micronutrient supplementation in pregnancy, as shown in a recent Cochrane review
covering clinical trials that included a total of over 141,000 participants [1], leads to a number of positive
effects in pregnancy, including a lowering of the prevalence of low birth weight babies, numbers born
small for gestational age (SGA), and the prevalence of preterm deliveries. Nineteen of the twenty
clinical trials included in this analysis took place in low- or middle-income countries where multiple
micronutrient deficiencies are prevalent during pregnancy. The remaining trial was conducted in
the UK, where a low-income population with nutritional deficiencies was studied, despite being in
a high-income country [2]. This trial found no effect of supplementation on low birth weight, SGA,
or preterm birth rates. However, it did report a reduced prevalence of anemia in pregnancy [2].
In contrast to the numbers of studies in low- and middle-income countries [3], formal studies are
rarely undertaken in high-income countries [4], such as the UK, where pregnant women may be better
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nourished [5]. Women from these countries may be more likely to be nutrient replete, running the
risk of adverse consequences arising from supplementation due to nutrient overload [6]. However,
individual women from such countries can still be undernourished or micronutrient deficient [7].
In this analysis, we investigated the potential effects of multiple micronutrient supplementation
on adverse maternal outcomes and offspring growth in a relatively contemporary pregnancy and birth
cohort recruited from a single center in Cambridge, UK [8]. This cohort came from a high-income
country, and indeed, the participants were generally less deprived than the national average for this
country [8]. The maternal participants also appeared to consume varied diets [9]. In the absence of
having detailed records of the nutritional status for this cohort, it should be noted that, in the UK
as a whole, at the start of recruitment in this cohort, younger adults (particularly women with low
socioeconomic statuses) showed relative trends for low micronutrient intakes [10].
2. Materials and Methods
2.1. Cambridge Baby Growth Study
The longitudinal Cambridge Baby Growth Study (CBGS) recruited women (and their partners and
offspring) attending early pregnancy ultrasound clinics at the Rosie Maternity Hospital, Cambridge,
UK between 2001–2009 [8]. This observational study was run prospectively (e.g., the collection of data
relating to size at birth and gestational diabetes (GDM)). However, in order to gain as much useful
information as possible, the measurements were supplemented with data collected retrospectively
(by one of the co-authors) from the participants’ hospital notes (e.g., those relating to blood pressure
outcomes). In addition, the index of multiple deprivation was derived from the postcode of the
participants’ home addresses as described [11]. In this cohort, 95.3% of the offspring were white,
1.7% were mixed race, 1.3% were black (African or Caribbean), and 1.7% were Asian.
Although 2229 pregnant women were originally recruited to the cohort, all of whom were over
16 years of age and able to give consent, 571 of them withdrew prior to the birth of their baby and
self-excluded from the study. From all of the women recruited to the CBGS during the years 2001–2009,
the following were excluded from the present analysis: those who gave birth to twins (because of
the impact of multifetal pregnancies on offspring size at birth), those that had already withdrawn
from the study before the birth of their baby, and those that did not fill in and return their pregnancy
questionnaire (specifically the question about supplement intake during pregnancy).
2.2. Ethical Approval
The CBGS was granted ethical approval by the Cambridge Local Research Ethics Committee,
Addenbrooke’s Hospital, Cambridge, UK (00/325). All procedures followed were in accordance with
the institutional and international guidelines. Written informed consent was obtained from all women
(on their own behalf and on behalf of their baby).
2.3. Assessment of Multiple Micronutrient Supplementation in Pregnancy
Each of the pregnant women were given an extensive questionnaire at recruitment to
fill in as pregnancy progressed (with assistance from trained research nurses if required) [9].
These questionnaires were collected by the research nurses after the birth of the babies. The questions
that were asked were wide-ranging, but as part of a section about lifestyle there was a question that
read “Have you taken any dietary supplements during the pregnancy?” If this was answered in the
affirmative, there was a table to fill in with “Name of Product”, “Frequency”, and “Gestational Weeks.”
Multiple micronutrient tablets (defined as tablets containing at least three micronutrients) were entered
as brand names; internet searches were subsequently performed (August–December 2019) by one
of the investigators to confirm brand constituent vitamins and minerals. The questionnaires were
completed by 1239 of the CBGS recruits, although not all participants provided unequivocal responses
to the question about dietary supplementation (these women were excluded from the present analysis).
Nutrients 2020, 12, 3466 3 of 13
Where a brand making multiple micronutrient supplements was listed without the full micronutrient
tablet name being entered onto the questionnaire, an assumption was made that the supplement
taken was the best-selling one from that brand. Exposed women were those who self-reported taking
multiple micronutrients at any stage of pregnancy. Non-exposed women were those who did not
supplement their diets with multiple micronutrients; they may either have not taken any dietary
supplements, or they may have taken single micronutrients, such as folic acid and/or iron.
2.4. Food Frequency Intakes in Pregnancy
Food frequency intakes were also collected from the pregnancy questionnaires [9]. As part of a
section of the questionnaire about lifestyle, there was a short (specific) food frequency questionnaire
which covered most of the major food and drink types. Regarding food, the participants were asked,
“How often did you eat the following foods during pregnancy?” and the response involved ticking one
of the following options: “never”, “1–3 times per month”, “1–3 times per week”, “4–6 times per week”,
or “once or more per day.” Regarding drinks, the participants were asked the number of times they
drank a particular drink per day or per week (depending upon the likely consumption frequency of
that drink).
2.5. Assessment of Pregnancy Outcomes
GDM was classified following overnight fasting and a standard 75 g oral glucose tolerance test
(OGTT) around week 28 of pregnancy in 1074 of the women [12] using the International Association of
Diabetes in Pregnancy Study Group diagnostic criteria [12,13]. Pre-eclampsia was classified using the
terms “preeclampsia”, “pre-eclampsia”, “PET”, or “pre-eclamptic toxemia”, and was recorded from
the hospital notes. It was clinically diagnosed using a combination of new-onset hypertension (systolic
blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg) after week 20 of pregnancy
and proteinuria (> 300 mg/day). Gestational hypertension was classified using a combination of hospital
notes and blood pressure measurements in the second half of pregnancy, as described previously [14].
This was achieved in 720 of the women. In other women, the hospital notes were either not available
to us or the hospital notes did not include blood pressure measurements from these pregnancies.
Low birth weight was defined as an unadjusted birth weight of less than 2.5 kg. SGA was defined as a
birth weight that was below the tenth percentile for gestational age against UK growth charts [15].
Premature birth was defined as one occurring before 37 weeks of gestation.
2.6. Assessment of Offspring Size at Birth
Birth weight was recorded from the hospital notes. Other newborn measurements (length,
head circumference, and skinfold thickness at four sites) were made by trained pediatric nurses as soon
as possible after birth (at a median (inter-quartile range) age of two (1–16) days). Each measurement
was made three times and the mean value was used. Body length was measured (to the nearest
0.1 cm) using a SECA 416 Infantometer. Head circumference was measured using a tape measure.
Triceps (posterior midline of upper left arm, halfway between the acromial process and the olecranon),
quadriceps (also known as thigh, found using a vertical line over the quadriceps muscle at midline of
the left thigh, halfway between the top of the patella and the inguinal crease), flank (also known as
supra-iliac, the diagonal plane in line with the natural angle of the iliac crest taken in the posterior
axillary line immediately posterior to the iliac crest), and subscapular (the oblique angle below the left
scapula) skinfold thicknesses were measured in triplicate on the left side of the body using Holtain
calipers (Chasmors Ltd., London, UK) [16]. Intra-observer technical errors of measurement were
0.4–2.8% for the skinfold thicknesses. Equivalent inter-observer values were 2.0–3.2%.
Body mass indexes (BMIs) were calculated as the height (or length for the newborn babies) divided
by the (pre-pregnancy for the mothers) weight squared. Ponderal indexes at birth were calculated as
the body length divided by the weight cubed.
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2.7. Data Availability
The dataset generated and/or analyzed during the current study is available in the Apollo
repository (https://doi.org/10.17863/CAM.54014).
2.8. Statistical Analysis
Risk ratios/relative risks (RRs) of adverse pregnancy outcomes by multiple micronutrient
supplementation were analyzed using logistic regression. Potential confounding of significant
associations by dietary intakes were investigated by adjusting these models for food frequency
intakes. Continuous variables were analyzed in statistical models using linear regression, adjusted for
confounders where appropriate. Where the dependent variable residuals were skewed, the models
were analyzed with prior transformation of the data so that the residuals were normally distributed.
Other categorical variables were analyzed using a χ2-test, Fisher’s exact test (as appropriate), or logistic
regression. RRs were calculated using the Stata binreg function. Missing data were dealt with
using case or listwise deletions, and p < 0.05 was considered statistically significant throughout.
The statistical analyses were performed using either Stata (version 13.1; Stata Corp., from Timberlake
Consultants Ltd., Richmond, Surrey, UK) or R (version 3.6.1; The R Foundation for Statistical Computing,
Vienna, Austria).
2.9. Sensitivity Analyses
Women who were diagnosed with anemia supplemented their diets with (presumably prescribed)
iron or folic acid. The various statistical analyses were also performed with women with anemia
excluded to test whether the evident trends were also present in those women whose multiple
micronutrient supplementation was unprescribed. Further sensitivity analyses were performed by
excluding women over 30 years of age to assess whether evident trends had an age-related basis,
and by excluding those women whose multiple micronutrient supplementation only began after they
had undergone OGTTs, assess whether it was associated with the development of GDM rather than
partially relating to a response to a diagnosis of GDM.
3. Results
3.1. Clinical Characteristics and Multiple Micronutrient Supplement Constituents
This analysis included 970 study participants (442 of whom did not supplement their diets
with multiple micronutrients and 528 that did). Of those that did supplement, 293 participants took
Vitabiotics Pregnacare, 206 took Sanatogen Pronatal, and 67 took Tesco Multiplus Pregnancy (some
women supplemented with more than one type; the constituents of these multiple micronutrient
supplements are shown in Table S1). A wide variety of other brands of supplements were taken by a
smaller number of participants (data not shown).
Those women included in the analysis were largely representative of the CBGS study participants
as a whole (Table S2). With the exception of the number of twin pregnancies, which were specifically
excluded from the analysis, only smoking during pregnancy differed in prevalence (in this case being
less common) between those included in the analysis than in those excluded from it. Smoking during
pregnancy, however, which was uncommon in this cohort of mothers [8], was not associated with any
key phenotype (data not shown).
Women who supplemented their diets with multiple micronutrients had very similar clinical
characteristics to those who did not supplement their diets with multiple micronutrients (Table 1).
The only trait that differed was the height, where the mean height was 1 cm taller in women who
supplemented their diets with multiple micronutrients.
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Table 1. A comparison of the characteristics of CBGS maternal participants who supplemented their
diets with multiple micronutrients during pregnancy and those that did not.


















(n = 391) (n = 468)
Weight gain in pregnancy (kg)
8.1 8.8
0.2(7.3–8.8) (8.1–9.5)
(n = 289) (n = 351)
Index of multiple deprivation
8.8 8.7
0.6(8.5–9.1) (8.5–9.0)
(n = 439) (n = 526)
Smoked during pregnancy (yes/no) 15/419 15/502 0.6
Anemia (n yes/no) 7/406 16/407 0.2
Length of Pregnancy (weeks)
39.8 40
0.1(39.7–40.0) (39.8–40.1)
(n = 434) (n = 517)
Data are mean (95% confidence interval) or number of participants.
3.2. Associations with Maternal Micronutrient Supplementation in Pregnancy
Of those women who supplemented their diets with multiple micronutrients, the majority of
them started supplementing either before or at the start of pregnancy, and continued supplementing
throughout pregnancy (Figure S1). Multiple micronutrient supplementation was strongly associated
with parity, with proportionally fewer women supplementing as the parity increased (no/yes,
in increasing order of parity: 163/258, 181/193, 67/55, 21/7, 1/2, and 1/1; p = 7.6 × 10−5).
Supplementing with multiple micronutrients was also associated with an increased risk of developing
GDM (p = 0.015; Figure 1). Excluding those participants whose multiple micronutrient supplementation
did not start until after the OGTTs took place did not substantially alter the statistical relationship
(RR = 1.87 (1.07–3.28); p = 0.03; n = 643). None of the food frequency intakes confounded this
relationship to any great extent (Table S3). With the exception of GDM, multiple micronutrient
supplementation was not associated with adverse pregnancy conditions or outcomes, such as
pre-eclampsia (p = 0.4), gestational hypertension (p = 0.7), low birth weight (p = 0.8), SGA (p = 0.8),
or premature birth (p = 0.2) (Figure 1).
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indices of offspring size at birth. 
Measure N Standardized β p-Value 
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BMI * 831 0.050 (−0.006–0.101) 0.08 
Ponderal Index * 831 0.038 (−0.015–0.088) 0.2 
Flank skinfold thickness * 833 0.067 (0.003–0.127) 0.04 
Quadriceps skinfold thickness * 834 0.042 (−0.010–0.095) 0.2 
Subscapular skinfold thickness * 833 0.068 (0.005–0.127) 0.03 
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pregnancy BMI. * Models additionally adjusted for age at assessment. 
Figure 1. Relative risks of various adverse conditions of pregnancy in women who supplemented their
diets with multiple micronutrients in pregnancy (* p < 0.05).
Maternal multiple micronutrient supplementation in pregnancy was associated with a number
of factors relating to increased size at birth and adiposity in the offspring (Table 2). This included
increased birth w ight, head circumference, and various skinfold thicknesses. Even the associations with
measurements where sta istical significance was no reac ed (e.g., with off pring BMI, ponderal index,
and body length) were all in the same direction, that of an increased size at birth.
Table 2. Associations between maternal micronutrients supplementation status in pregnancy and
indices of offspring size at birth.
Measure N Standardized β p-Value
Weight 855 0.063 (0.005–0.123) 0.03
Length * 833 0.032 (−0.018–0.081) 0.2
Head Circumference * 834 0.053 (0.002–0.100) 0.04
BMI * 831 0.050 (−0.006–0.101) 0.08
Ponderal Index * 831 0.038 (−0.015–0.088) 0.2
Flank skinfold thickness * 833 0.067 (0.003–0.127) 0.04
Quadriceps skinfold thickness * 834 0.042 (−0.010–0.095) 0.2
Subscapular skinfold thickness * 833 0.068 (0.005–0.127) 0.03
Triceps skinfold thickness * 833 0.095 (0.030–0.155) 3.0 × 10−3
Standardized βs are presented as means (95% confidence intervals). All models adjusted for gestational age at birth,
parity, smoking during pregnancy, offspring sex, and maternal pre-pregnancy BMI. * Models additionally adjusted
for age at assessment.
3.3. Subgroup Analysis in Women Who Underwent OGTTs
In women for whom OGTT data were available, except for the association with head circumference,
all of the associations appeared attenuated by adjusting for GDM (Table 3). Even prior to this adjustment,
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all of the associations were already attenuated relative to those using the full dataset in this smaller
subset of study participants.
Table 3. Subgroup comparison assessing the effect of GDM on associations between multiple
micronutrient supplementation in pregnancy and size at birth.
Measure N
Unadjusted for GDM Adjusted for GDM
Standardized β p-Value Standardized β p-Value
Weight 600 0.048 (−0.021–0.112) 0.2 0.031 (−0.037–0.095) 0.4
Length * 583 0.009 (−0.050–0.067) 0.8 0 (−0.058–0.059) 1.0
Head Circumference * 584 0.035 (−0.022–0.097) 0.3 0.036 (−0.022–0.098) 0.3
BMI * 582 0.046 (−0.021–0.109) 0.2 0.034 (−0.032–0.097) 0.3
Ponderal Index * 582 0.042 (−0.022–0.104) 0.2 0.034 (−0.029–0.097) 0.3
Flank skinfolds thickness * 584 0.040 (−0.038–0.112) 0.3 0.022 (−0.055–0.093) 0.6
Quadriceps skinfolds thickness * 585 0.042 (−0.022–0.106) 0.3 0.034 (−0.030–0.099) 0.4
Subscapular skinfolds thickness * 584 0.061 (−0.015–0.128) 0.1 0.052 (−0.025–0.119) 0.2
Triceps skinfolds thickness * 584 0.058 (−0.021–0.123) 0.1 0.050 (−0.029–0.116) 0.2
Values in the table only include data from pregnancies where GDM status was available. Standardized βs
are presented as means (95% confidence intervals). All models adjusted for gestational age at birth, parity,
smoking during pregnancy, offspring sex, and maternal pre-pregnancy BMI. * Models additionally adjusted for age
at assessment.
3.4. Sensitivity Analyses
Significant associations with maternal GDM and increased offspring size at birth and adiposity
were still evident even when women with anemia were excluded from the analyses (Table 4).
Table 4. Associations of micronutrient supplementation in pregnancy with (a) outcomes of pregnancy
and (b) offspring size at birth and adiposity in women and babies without anemia.
(a)
Pregnancy Outcome N (yes/no) Risk Ratio p-Value
GDM 63/556 1.85 (1.11–3.10) 0.02
Pre-eclampsia 14/879 0.63 (0.22–1.79) 0.4
Gestational Hypertension 24/420 0.99 (0.45–2.15) 1.0
Low Birth Weight 23/859 0.91 (0.41–2.04) 0.8
SGA 4/878 2.50 (0.26–23.95) 0.4
Premature Birth 15/869 0.56 (0.20–1.56) 0.3
(b)
Measure N Standardized β p-Value
Weight 796 0.065 (0.004–0.118) 0.04
Length * 776 0.041 (−0.011–0.092) 0.1
Head Circumference * 776 0.045 (−0.001–0.099) 0.08
BMI * 774 0.043 (−0.014–0.096) 0.1
Ponderal Index * 774 0.027 (−0.027–0.080) 0.3
Flank skinfolds thickness * 776 0.074 (0.008–0.137) 0.03
Quadriceps skinfolds thickness * 776 0.055 (−0.003–0.108) 0.07
Subscapular skinfolds thickness * 776 0.066 (0.002–0.128) 0.045
Triceps skinfolds thickness * 776 0.098 (0.032–0.161) 3.3 × 10−3
Data are mean (95% confidence interval) or number of participants. All models in (b) adjusted for gestational age at
birth, parity, smoking during pregnancy, offspring sex, and maternal pre-pregnancy BMI. * Models additionally
adjusted for age at assessment.
The increased risk of developing GDM associated with multiple micronutrient supplementation
in pregnancy was still evident in mothers less than 30 years of age (Table 5). The number of women
with adverse pregnancy outcomes who were less than 30 years of age were very low, as only a minority
of pregnancies in the CBGS involved women in this age category. The only measure of adiposity that
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still showed a statistically significant association with multiple micronutrient supplementation in this
small number of pregnancies was the subscapular skinfold thickness. Apart from associations with the
offspring BMI and ponderal indexes, the standardized effect sizes of the other associations increased
(in the same direction) relative to those in the full analysis, albeit without statistical significance in the
small number of women tested.
Table 5. Associations of micronutrient supplementation in pregnancy with (a) outcomes of pregnancy
and (b) offspring size at birth and adiposity in women and babies where the mother was less than
30 years of age.
(a)
Pregnancy Outcome N (yes/no) Risk Ratio p-Value
GDM 17/99 3.03 (1.05–8.75) 0.04
Pre-eclampsia 2/159 1.12 (0.07–17.57) 0.9
Gestational Hypertension 6/79 1.58 (0.34–7.35) 0.6
Low Birth Weight 3/158 0.56 (0.05–6.04) 0.6
SGA 1/160 N/A
Premature Birth 2/159 N/A
(b)
Measure N Standardized β p-Value
Weight 144 0.071 (−0.074–0.211) 0.3
Length * 141 0.067 (−0.056–0.184) 0.3
Head Circumference * 140 0.098 (−0.023–0.211) 0.1
BMI * 141 0.006 (−0.125–0.136) 0.9
Ponderal Index * 141 −0.021 (−0.139–0.100) 0.7
Flank skinfolds thickness * 141 0.090 (−0.057–0.233) 0.2
Quadriceps skinfolds thickness * 141 0.097 (−0.035–0.218) 0.2
Subscapular skinfolds thickness * 141 0.173 (0.029–0.314) 0.02
Triceps skinfolds thickness * 141 0.131 (−0.019–0.251) 0.09
Data are mean (95% confidence interval) or number of participants. N/A = not available. All models in (b) adjusted
for gestational age at birth, parity, smoking during pregnancy, offspring sex, and maternal pre-pregnancy BMI.
* Models additionally adjusted for age at assessment.
4. Discussion
In this analysis, maternal multiple micronutrient supplementation in pregnancy in a population
from a high-income country was associated with increased risk of GDM in the mother. It was
also associated with results that are suggestive of increased offspring size at birth and adiposity.
The consensus from previous studies in this area is that such supplementation is associated with
reduced risk of offspring low birth weight and possibly reduced risk of the offspring being born
SGA [1]. Consistent with a randomized trial that also took place in the UK [2], we could not replicate
these associations in our population, which only had a relatively small number of low birth weight and
SGA pregnancies. However, our associations are at least consistent with the idea that a generalized
increased size at birth across a whole population could lead to a lower proportion of low birth weight
and SGA pregnancies in offspring that otherwise would be close to the boundaries of definitions for
these adverse outcomes of pregnancy.
Deficiencies in specific micronutrients, such as selenium, chromium, and zinc, have previously
been shown to be associated with an increased risk of developing GDM [17]. Multiple micronutrient
supplementation in pregnancy might therefore be expected to reduce the incidence of GDM, although it
appears not to have been investigated before. In our population, however, it was associated with
an increased incidence of GDM. As our supplementation data was grouped to cover the whole of
pregnancy, it is possible that the association partially relates to women with diagnosed GDM wanting
to try to improve their diets, and supplementing with multiple micronutrient was part of this. However,
the vast majority of the women who supplemented their diets with multiple micronutrients in this
analysis started this either prior to or early in pregnancy, and the significant association was still evident
Nutrients 2020, 12, 3466 9 of 13
when excluding women who only started supplementing after their OGTTs had taken place. It seems,
therefore, that the association with GDM, rather than resulting from the GDM, actually relates to its
development. Although this analysis was limited by not having access to highly detailed nutritional
status records, as far as we can tell, the risk that we observed was not confounded by diet, as the food
frequency intakes (specific and limited as they were [9]) did not substantially change the relationship
between multiple micronutrient supplementation in pregnancy and GDM development. Whilst we
are not aware of any studies that have previously assessed the risk of GDM development in those
women supplementing their diets with multiple micronutrients (in high-income countries), some of
the individual micronutrients (such as folic acid and iron) have been associated with the development
of GDM in other studies [18–21], or even with protection against its development (vitamin D [22] and,
in contrast to other studies [20,21], folic acid [23]). Although links between multiple micronutrient
supplementation and GDM in pregnancy have not been investigated previously, one study found a
lack of association with pregnancy-induced hypertension [24], which we were able to confirm in the
present analysis in terms of both pre-eclampsia and gestational hypertension.
Previous studies have shown associations between multiple micronutrient supplementation
in pregnancy and increased size at birth, particularly birth weight and head circumference [25–28].
Results from the present analysis are consistent with these. Along with increases in birth weight and
head circumference in women supplementing their diets with multiple micronutrients, for the first time,
this analysis has shown increases in adiposity through skinfolds thickness measurements, albeit with
possible regionalized differences due to the lack of association with quadriceps skinfolds thicknesses.
Previously, no changes in offspring adiposity have been observed with maternal multivitamin
supplementation [29], suggesting that the increased adiposity observed in the present analysis may
relate to one or more of the minerals commonly found in multiple micronutrient preparations.
The mechanism of how multiple micronutrient supplementation may lead to increased adiposity
is not fully understood. However, results from the present analysis in the subset of women who
underwent OGTTs suggest that it may involve the same mechanisms that lead to increased offspring
size at birth in GDM pregnancies in this cohort [30], as nearly all of the associations between multiple
micronutrient supplementation and increased size at birth appeared attenuated by adjustment for GDM.
This attenuation was not evident for the association with head circumference, suggesting that other
mechanisms may also be involved, although the overall effect sizes of these alternative mechanisms
are likely to have been smaller.
This analysis was not able to, nor was it designed to, distinguish which of the constituents of
multiple micronutrient preparations caused the increased size at birth and GDM risk, or whether
there was an interactive effect of two or more of the micronutrients that did this. It also grouped
together different multiple micronutrient brands, all of which contained at least three micronutrients
and most of which contained at least 15 of them. The various preparations contained different
micronutrients, different salts of the same micronutrients, or these micronutrients at different amounts.
However, most pregnancy multiple micronutrient preparations are somewhat similar, and by grouping
them together in this analysis, we had enough statistical power in the present analysis to detect
differences in various indices of offspring size at birth and risk of maternal GDM. This analysis
did not have access to whether the micronutrient supplementation was prescribed or unprescribed.
However, sensitivity analyses that excluded women reporting anemia in pregnancy (who would have
been prescribed with iron or folic acid) showed similar trends to those observed in the full analysis,
suggesting that this may not have biased the results.
Another potential limitation of the analysis could be possible biases introduced by its recruitment
and analytical strategies. However, while the participants of the current analysis were not individually
matched, the clinical characteristics of the group that supplemented with multiple micronutrients
were very similar to those that did not supplement. The clinical characteristics of the whole group of
participants in the present analysis were also very similar to those of women recruited to the CBGS
who were excluded from it. In turn, the clinical characteristics of women recruited to the CBGS were
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representative of the whole population of women attending the Rosie Maternity Hospital, Cambridge,
with the exception that they tended to be a little bit older and were more likely to be primiparous [8].
The relatively older age may not have affected our analysis, however, as sensitivity analyses that
excluded women above 30 years of age showed increased effect sizes of associations with skinfold
thicknesses, as well as a significantly increased risk of GDM development in the younger women.
Whilst the associations with skinfold thicknesses did not reach statistical significance, this may have
been due to a lack of statistical power in the small number of younger women tested. A further
limitation of the analysis could relate to biases introduced by missing data, the extent of which varied
by measurement, as well as the unavailability of data pertaining to familial history of diabetes or
previous GDM, both risk factors for the development of GDM. In this analysis, missing data were dealt
with by case or listwise deletions in order to prevent the introduction of inaccuracies resulting from
data imputation. However, this may have introduced biases which are unfortunately common in this
type of cohort study [31].
Other limitations of the current analysis include the facts that the micronutrient supplementation
was self-reported, and that limited account was taken as to when in pregnancy and for how long
supplementation took place. However, at least as far as supplementation specifically with folic acid in
pregnancy, self-reporting has been validated as accurate [32,33]. In women with at least 12 years of
education, one cohort also found that self-reporting of iron supplementation in pregnancy displayed
high specificity [34]. In the present analysis, all 566 participants who responded to a question about
their education in their pregnancy questionnaire reported that they had at least 12 years of education
(data not shown), suggesting that for self-reporting of iron supplementation at least, high specificity
could also have been achieved in the present analysis. Although only limited use of the timing and
length of multiple micronutrient supplementation was made in this study, more than 80% of the
respondents who supplemented with multiple micronutrients did so for more than half the pregnancy,
which suggests that misclassification (due to only supplementing for a short period of time) is unlikely
to have significantly affected the results. Finally, the cohort was recruited at the beginning of this
century, and differences in dietary trends between then and now may limit the relevance of the results
to the present age. Indeed, we previously observed some temporal trends in pregnancy dietary habits
over the course of the recruitment period in the women studied in the present analysis [9]. However,
the effect sizes of these trends were very small, and even if they continued at the same rate after
the recruitment period, would not have severely limited the relevance of the current analysis to the
present age.
5. Conclusions
In conclusion, in this analysis, we found evidence that maternal micronutrient supplementation
in pregnancy is associated with increased size at birth and adiposity in the offspring in a population
from a high-income country. It was also associated with increased risk of developing GDM in the
mother, and the mechanisms that link GDM with increased size at birth may be partially responsible
for the increased size at birth and adiposity resulting from maternal micronutrient supplementation
in pregnancy.
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